Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...
Compass Pathways on Tuesday disclosed results from two Phase 3 studies that support a potential approval of its psilocybin treatment for severe depression, but more detailed data are needed to ...
Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy met the main goal in a late-stage study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results